The purpose of the study is to gain experience of a patient management pathway in patients with heart failure including protocolized medications from an integrated device diagnostic-based risk stratification algorithm based on the data collected by the Reveal LINQ device. The study will evaluate use of the LINQ Heart Failure Risk Status algorithm to guide patient care in subjects with class II or III congestive heart failure.

ANALOG: Feasibility and Efficacy Study of the CardioPulmonary Management (CPM) System in Patients with Chronic Heart Failure

The primary objective of this study is to assess the safety and efficacy of the VITARIA™ system when added to stable, guideline-directed medical therapy for patients with heart failure and reduced heart muscle function.

The purpose of this clinical investigation is to develop valid scientific evidence for the safety and effectiveness of the BAROSTIM NEO System delivered by the BATwire Implant Kit (BATwire Kit) in subjects with heart failure.

This study is a multicenter, randomized, double-blind , placebo-controlled trial to evaluate the effect of in-hospital initiation of Dapagloflozin on clinical outcomes in patients with heart failure who have been stabilized during hospitalization for acute heart failure.

The objective of this study is to prospectively compare decongestive therapy administered by the Reprieve DMS system to Optimal Diuretic Therapy (ODT) in the treatment of patients diagnosed with acute decompensated heart failure (ADHF). The main objective is to determine if the Reprieve DMS can more efficiently decongest ADHF patients in comparison to Control Therapy.